Outcomes of IVIG monotherapy on non-paraneoplastic autoimmune retinopathy

Can J Ophthalmol. 2024 Feb;59(1):e101-e104. doi: 10.1016/j.jcjo.2023.08.001. Epub 2023 Sep 5.

Authors

Avery Zhou¹, Carla Fernández-Santos¹, Andrew Dolinko¹, Andrew M Philip¹, C Stephen Foster²

Affiliations

¹ Massachusetts Eye Research and Surgery Institution, Waltham, MA; Ocular Immunology and Uveitis Foundation, Waltham, MA.
² Massachusetts Eye Research and Surgery Institution, Waltham, MA; Ocular Immunology and Uveitis Foundation, Waltham, MA; Harvard Medical School, Boston, MA. Electronic address: sfoster@mersi.com.

PMID: 37683692
DOI: 10.1016/j.jcjo.2023.08.001

No abstract available

Publication types

Letter

MeSH terms

Autoantibodies
Autoimmune Diseases* / diagnosis
Autoimmune Diseases* / drug therapy
Humans
Immunoglobulins, Intravenous / therapeutic use
Paraneoplastic Syndromes*
Retinal Diseases* / diagnosis
Retinal Diseases* / drug therapy

Substances

Immunoglobulins, Intravenous
Autoantibodies